הכנסה תפעולית לפני ניכוי פחת: cytekbio.com (CTKB)

Cytek Biosciences, Inc. (CTKB) leads in spectral cell analysis thanks to its proprietary software. Production relies on external contractors for module assembly and logistics. Stable cash flow from instrument sales fully funds research and development. Total EBITDA for the period on this chart demonstrates real profitability, where 0.00 characterizes this operating profit valuation parameter.

Investors utilize asset filtering based on free cash flow to weed out illiquid companies. This metric measures operational efficiency by excluding non-cash depreciation charges and accounting adjustments. For Cytek Biosciences, Inc. (CTKB), this reflects the ability to generate cash while covering costs for specialized medical logistics and system calibration. Profit growth confirms market expansion. By analyzing the trend of gross operating profit before wear and tear, one can assess the risk of capital stagnation.